VivoSeq
Other

GLP-1

0

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

GLP-1 is an early-stage landscape with 0 programs across 1 company. The most active players are Novo Nordisk.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

46

clinical trials

Completed28 · 61%
Unknown status6 · 13%
Terminated4 · 9%
Not yet recruiting4 · 9%
Recruiting3 · 7%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

46 trials

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Recruiting·—·N/A·NCT07309094·250 enrolled
Impact GLP-1 Agonists Following Bariatric
Recruiting·UUniversity of Missouri-Columbia·Phase 4·NCT06132477·150 enrolled
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Recruiting·—·Phase 2·NCT05356104·110 enrolled
GLP-1s to Enhance Lasting Optimal Weight
Active, not recruiting·WWake Forest University Health Sciences·Phase 4·NCT06861439·40 enrolled
Impact of GLP-1 Receptor Agonists on Patients With IPMN
Not yet recruiting·HHôpital Fribourgeois·N/A·NCT07014709·30 enrolled
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Not yet recruiting·VVanderbilt University Medical Center·Phase 2·NCT07221214·200 enrolled
GLP-1R Actions on Muscle and the Skeleton
Not yet recruiting·PPennington Biomedical Research Center·Phase 3·NCT07154719·50 enrolled
Lifestyle Change Implementation Research Network at PRC at UMass Chan
Not yet recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT07481305·220 enrolled
Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion
Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02445508·15 enrolled
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01507597·30 enrolled
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT01967589·82 enrolled
GLP-1 Medicines and Mental Health Changes
Completed·UUniversity of California, San Diego·N/A·NCT07368855·90 enrolled
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03018444·15 enrolled
Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
Completed·—·Phase 1·NCT02749032·24 enrolled
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
Completed·UUniversity of Washington·Phase 4·NCT01524705·102 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)